| DIRECT COMPETITOR COMPARISON | |
| CSII | ABT | BSX | EVVV | Industry | | Market Cap: | 72.87M | 82.55B | 12.81B | 1.46B | 97.36M | | Employees: | 239 | 72,000 | 24,800 | 1,250 | 65 | | Qtrly Rev Growth (yoy): | 30.50% | 3.50% | 2.40% | 5.40% | 19.70% | | Revenue (ttm): | 60.01M | 29.92B | 8.11B | 428.44M | 14.01M | | Gross Margin (ttm): | 73.67% | 58.31% | 66.97% | 70.85% | 65.68% | | EBITDA (ttm): | -26.03M | 8.64B | 2.11B | 46.30M | -12.25M | | Oper Margins (ttm): | -44.23% | 22.32% | 15.67% | 2.30% | -137.11% | | Net Income (ttm): | -1.62M | 5.60B | -2.34B | -262.20M | N/A | | EPS (ttm): | -0.154 | 3.691 | -1.556 | -2.462 | -0.31 | | P/E (ttm): | N/A | 14.46 | N/A | N/A | 17.26 | | PEG (5 yr expected): | N/A | 1.25 | 1.12 | 2 | 1.28 | | P/S (ttm): | 1.21 | 2.75 | 1.58 | 3.43 | 9.82 |
|
| ABT = Abbott Laboratories | | BSX = Boston Scientific Corporation | | EVVV = ev3, Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.72 | -0.38% | 56.40B | 12.15 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.98 | -0.17% | 13.88B | 16.06 | | Genzyme Corp. | GENZ | 49.18 | -0.49% | 13.05B | 28.04 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 45.95 | -0.37% | 41.35B | 17.77 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.90 | 0.06% | 8.90B | 1018.37 | | Teva Pharmaceutical Industries Limited | TEVA | 52.39 | -0.10% | 46.16B | 47.93 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.70 | -0.19% | 4.00B | 19.43 | | King Pharmaceuticals Inc. | KG | 11.45 | 1.33% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.12 | -0.11% | 5.54B | 111.17 | | Pfizer Inc. | PFE | 18.18 | 2.36% | 146.70B | 15.10 | | Johnson & Johnson | JNJ | 64.28 | 0.05% | 177.35B | 14.04 | | GlaxoSmithKline plc | GSK | 41.58 | -1.12% | 105.41B | 13.24 | | Sanofi-Aventis | SNY | 38.886 | 0.40% | 101.54B | N/A | | Novartis AG | NVS | 54.84 | -0.89% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 40.95 | 0.37% | N/A | N/A | | AstraZeneca plc | AZN | 45.45 | -0.55% | 65.90B | 9.13 | | Abbott Laboratories | ABT | 53.37 | 0.24% | 82.55B | 14.46 | | Bristol-Myers Squibb Co. | BMY | 25.0511 | 0.61% | 49.63B | 12.96 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ABT | | Becton Receives FDA Clearance
Wed 11:08am -
Zacks.com | | • | BSX | | Deal Journal Video: A Decade of Deal Making
Wed 10:12am -
at The Wall Street Journal Online | | • | BSX | | Billionaire Paulson Still Hungry for Stocks
Wed 9:49am -
Indie Research | | • | ABT | | Hospital Stocks And Other Key Health Care Sectors Benefit Under Obamacare According To Lazard Capital
Wed 9:11am -
Wall Street Transcript | | • | ABT | | Stock-Picking Freedom Helps Lord Abbett
Wed 8:45am -
at TheStreet.com | | • | ABT | | The Stock Screaming "Buy Me!"
Wed 7:00am -
at Motley Fool | | • | ABT | | These Stocks Are Growth Traps
Tue 4:16pm -
at Motley Fool | | • | ABT | | U.S. Medicare to pay for HIV testing
Tue 3:50pm -
at Reuters | | • | BSX | | New Product from St. Jude
Mon, Dec 7 -
Zacks.com | | • | BSX | | A Decade of Buyout Busts
Fri, Dec 4 -
at Fox Business | | • | BSX | | Drink In These 5 Top Stocks
Fri, Dec 4 -
at Motley Fool | | • | BSX | | Paulson & Co's Latest Portfolio: 13F Filing
Fri, Dec 4 -
at Seeking Alpha | | • | BSX | | Health-Care Reform Is Very Taxing
Thu, Dec 3 -
at Motley Fool | | • | BSX | | Executive Bonuses Must Go
Thu, Dec 3 -
at Investopedia | | • | EVVV | | ev3 Inc. to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
Tue, Nov 24 -
GlobeNewswire | | • | EVVV | | ev3 Inc. to Present at the 2009 Citi Investment Research Small and Mid Cap Conference on November 19, 2009
Thu, Nov 12 -
GlobeNewswire | | • | EVVV | | Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
Tue, Nov 10 -
Wall Street Transcript | | • | EVVV | | EV3 INC. Financials
Fri, Nov 6 -
EDGAR Online Financials | | • | EVVV | | EV3 INC. Files SEC form 10-Q, Quarterly Report
Tue, Nov 3 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.26% Nasdaq 
Competitors
